Wragge Lawrence Graham & Co
- Company/Commercial (91)
- Litigation / Dispute Resolution (41)
- Banking / Finance (39)
- Regulatory and compliance (27)
- Employment (22)
- Real Estate (22)
- Financial services (21)
- Funds (20)
- Tax (16)
- Information Technology (14)
- Construction (13)
- Private Equity (11)
- Energy (10)
- Insolvency & restructuring (10)
- Competition/EU (9)
- Intellectual Property (9)
- PPP/PFI/Commercial projects (9)
- In-House (8)
- Pharma/Biotech (8)
- Crime (7)
- Pensions (7)
- Public Sector/Local Authority (7)
- Planning (6)
- Commodities (5)
- Insurance/reinsurance (5)
- Transport (Including aviation and shipping) (5)
- Environment (4)
- Healthcare (4)
- Business Tax (3)
- Personal tax / Trusts (3)
- Telecoms (3)
- Family (2)
- Media/Entertainment/Sport (2)
- Charities (1)
- Human Rights (1)
- Immigration (1)
- Privacy and reputation (1)
- Private Client (1)
- Professional Indemnity/Negligence (1)
- Travel and Tourism (1)
Sort By: Newest first | Oldest first
Wragge Lawrence Graham & Co’s life sciences experts have advised AstraZeneca on its definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease medicine.
How provisional sums are dealt with in the most common forms of construction contract.
Welcome decision redresses the previous imbalance between patentee and prospective licensee.
Also: reporting unenforceable credit agreements; ADR directive; and more.
Two ways an employer can try to deal with the risk of contractor default. Includes practical tips.
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Wragge Lawrence Graham & Co’s employment &and equalities experts bring you the latest developments that may affect your business – what they are, an...
A cautionary word on the pitfalls of local agreements in relation to payment under a construction contract.
In the first of a two-part series Wragges takes a look at whether a US stock-option-linked non-compete clause will be effective to restrain an executive in a UK subsidiary. There is a good chance the answer is no.
Wragges considers the position you may be in if there has been an error in the execution of a contract, and provides a guide for some of the common mishaps that you may encounter.
Wragge Lawrence Graham & Co’s corporate team has acted for Gigaclear plc on a £30m investment to expand its provision of ultrafast fibre-to-the-premises networks to rural communities.
Wragge Lawrence Graham & Co has advised AstraZeneca on a co-development and commercialisation agreement with Innate Pharma SA, a biopharmaceutical company developing therapeutic antibodies for the treatment of cancer.
The cross-sector energy team at Wragge Lawrence Graham & Co has advised established client Grid Essence on the sale of a portfolio of eight solar PV parks and the subsequent refinancing of the projects.
The defence of illegality – which prevents a claimant from bringing a claim that arises out of its own illegal acts – can’t be used where the company is claiming against its directors.
Law returns to pre-Woolworths litigation position; employers must look at the ‘establishment’ question.
A lesson for employers dealing with pension changes: remembering three Ps – proposal, privilege and protection – can minimise legal risk.
Wragge Lawrence Graham & Co has advised AIM-traded Staffline on its £34.5m acquisition of A4e Ltd, creating one of the UK’s largest Work Programme providers.
Wragge Lawrence Graham & Co has promoted six new partners, enhancing its capability in corporate, energy, dispute resolution and real estate.
Sanctions for regulatory offences, particularly for larger corporates, set to increase substantially.
In the past two months Wragge Lawrence Graham & Co’s corporate team has acted for two special purpose acquisition companies on admission to the UK Listing Authority’s Official List and to the London Stock Exchange’s main market.